← ANALYST RATINGS · TIPRANKS
Eton Pharmaceuticals (ETON): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy0 Hold0 Sell
Ratings of 3 analysts in the last 3 months12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $71.33, the highest $76.00, the lowest $68.00. The average is +41.8% from the last price of $50.31.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Gary Nachman★★★★★★★★★★#7384 · hits 47% · avg +0.3% | Canaccord Genuity | $60.00 → $68.00+13.3% | Buy | +35.2% | Reiterated | 14.10.26on TipRanks Oct 15 07:30 | +0.2%next day −3.2% | ↗ |
| AI xAi Drug Manufacturers - Specialty and GenericxAI Grok-3 | TipRanks - xAI | $57.00 → $60.00+5.3% | Buy | +19.3% | Reiterated | 14.10.26on TipRanks 16:05 | — | |
| AI DeepSeek Drug Manufacturers - Specialty and GenericDeepSeek R1-0528 | TipRanks - DeepSeek | $58.00 → $60.00+3.4% | Buy | +19.3% | Reiterated | 14.10.26on TipRanks 16:05 | — | |
| AI OpenAI Drug Manufacturers - Specialty and GenericOpenAI 4o | TipRanks - OpenAI | $57.00 → $59.00+3.5% | Buy | +17.3% | Reiterated | 14.10.26on TipRanks 16:05 | — | |
| AI Anthropic Drug Manufacturers - Specialty and GenericAnthropic Opus-4.1 | TipRanks - Anthropic | $55.00 → $57.00+3.6% | Hold | +13.3% | Reiterated | 14.10.26on TipRanks 16:05 | — | |
| AI Google Drug Manufacturers - Specialty and GenericGemini 2.5Pro | TipRanks - Google | $58.00 → $62.00+6.9% | Buy | +23.2% | Reiterated | 14.10.26on TipRanks 16:05 | — | |
| AI PerPlexity Drug Manufacturers - Specialty and GenericPerPlexity SonarPro | TipRanks - PerPlexity | $58.00 → $60.00+3.4% | Buy | +19.3% | Reiterated | 14.10.26on TipRanks 16:05 | — | |
| Swayampakula Ramakanth★★★★★★★★★★#445 · hits 47% · avg +21.2% | H.C. Wainwright | $70.00 | Buy | +39.1% | Reiterated | 14.10.26on TipRanks 12:55 | +0.2%next day −3.2% | ↗ |
| Chase Knickerbocker★★★★★★★★★★#75 · hits 59% · avg +36.2% | Craig-Hallum | $62.00 → $76.00+22.6% | Buy | +51.1% | Reiterated | 14.08.26on TipRanks Aug 13 09:35 | −2.6%next day +44.5% · 5 days +48.8% | ↗ |
| Madison Elsaadi★★★★★★★★★★#984 · hits 54% · avg +35.6% | B. Riley Securities | $40.00 | Buy | −20.5% | Reiterated | 25.06.26on TipRanks Jun 26 13:30 | +2.3%next day +3.3% · 5 days +6.3% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Eton Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $68.67 at a price of $51.49 (+33.4%); now: $71.33 at $50.31 (+41.8%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 2 | 3 | 1 | 1 | 0 |
| Buy | 9 | 7 | 8 | 6 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.31 (from $0.25 to $0.40). Last quarter: $0.35.
Sales
Next quarter’s sales estimate — $42M (from $40M to $43M). Last quarter: $38M.
Best top-analyst consensus in the sector · Healthcare
About Eton Pharmaceuticals
- CEO: Sean E. Brynjelsen
- Employees: 44
- 21925 W. Field Parkway, Deer Park, IL, 60010-7278, US
- www.etonpharma.com
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Data from the stock’s TipRanks forecast page, read 155 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗